Xanomeline Tartrate
Xanomeline tartrate is the tartrate salt form of xanomeline, a selective M1/M4 muscarinic receptor agonist being developed for schizophrenia and Alzheimer's disease. The tartrate salt form is used in the combination product with trospium chloride (KarXT/Cobenfy), where xanomeline provides central therapeutic muscarinic agonism while trospium blocks peripheral muscarinic receptors to reduce gastrointestinal side effects. This combination approach enables effective central muscarinic activation with an acceptable safety profile.
Moleküler Ağırlık
431,5000 g/mol
TPSA
182,00 Ų
Terapötik Alanlar
Etki Mekanizması
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCCCCCOc1nsnc1C1=CCCN(C)C1.O=C(O)C(O)C(O)C(=O)O
InChI
InChI=1S/C14H23N3OS.C4H6O6/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12;5-1(3(7)8)2(6)4(9)10/h8H,3-7,9-11H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)
Molecular Formula
C18H29N3O7S
HBD / HBA
4 / 11
Döndürülebilir Bağlar
10
Ağır Atomlar
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Xanomeline tartrate is the tartrate salt form of xanomeline, a selective M1/M4 muscarinic receptor agonist being developed for schizophrenia and Alzheimer's disease. The tartrate salt form is used in the combination product with trospium chloride (KarXT/Cobenfy), where xanomeline provides central therapeutic muscarinic agonism while trospium blocks peripheral muscarinic receptors to reduce gastrointestinal side effects. This combination approach enables effective central muscarinic activation with an acceptable safety profile.
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Xanomeline Tartrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2336050. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71456. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="xanomeline-tartrate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/xanomeline-tartrate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/xanomeline-tartrate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/xanomeline-tartrate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="xanomeline-tartrate"></drugfyi-drug>